Orion S.A.
No SEC Form 4 filings for $OEC in the last 30 days.
See all $OEC insider activity →Orion Corporation (OEC) reported interim Phase III results showing that darolutamide, combined with ADT and RT, reduced the risk of metastasis or death by 58% in high-risk recurrent prostate cancer. The 4-year metastasis-free survival rate was 95% compared to 88%. Darolutamide is not yet approved for this use.
Orion Corporation (OEC) raised its 2026 sales and EBIT outlook, citing stronger-than-expected royalty income. Net sales are now projected at €2.07B–€2.14B, up from €2.00B–€2.10B, and operating profit at €730M–€790M, up from €650M–€750M.
Orion Corporation (OEC) partnered with Qilu Pharma Europe to distribute, market, and sell Qilu's IV pembrolizumab biosimilar in Europe. Qilu will supply the product and receive profit shares, plus development, regulatory, and sales milestones. This expands Orion's oncology generics/biosimilars presence in Europe, though revenue targets are not yet quantified.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OEC (Orion S.A.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent OEC coverage spans earnings, financial news and corporate actions.
Positive Phase III data may drive significant upside as investors price in potential regulatory approval and expanded market opportunity.
Guidance upgrade may lift sentiment but the numbers were already public weeks ago, limiting price impact.
The deal adds a new oncology biosimilar to Orion's pipeline, offering modest upside if regulatory approval and launch succeed.
The dividend declaration may attract income-focused investors and provide a modest upside to the stock.
Q2 commentary and retained guidance highlight margin pressure in Rubber, offset by working-capital and cost actions, with a key timing catalyst in Europe.
AlphAI scores every news story that mentions OEC with an AI model for sentiment and relevance, and aggregates insider trades from Orion S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Orion Corporation (OEC) reported interim Phase III results showing that darolutamide, combined with ADT and RT, reduced the risk of metastasis or death by 58% in high-risk recurrent prostate cancer. The 4-year metastasis-free survival rate was 95% compared to 88%. Darolutamide is not yet approved for this use.
1 min readOrion Corporation (OEC) raised its 2026 sales and EBIT outlook, citing stronger-than-expected royalty income. Net sales are now projected at €2.07B–€2.14B, up from €2.00B–€2.10B, and operating profit at €730M–€790M, up from €650M–€750M.
1 min readOrion Corporation (OEC) partnered with Qilu Pharma Europe to distribute, market, and sell Qilu's IV pembrolizumab biosimilar in Europe. Qilu will supply the product and receive profit shares, plus development, regulatory, and sales milestones. This expands Orion's oncology generics/biosimilars presence in Europe, though revenue targets are not yet quantified.
1 min readOrion S.A. (OEC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 FOR IMMEDIATE RELEASE: September 17, 2026 Orion S.A. Declares Interim Quarterly Dividend HOUSTON – Orion S.A. (NYSE: OEC), a global specialty chemicals company, today announced that its Board of Directors has declared an interim dividend to be paid in the first quart
1 min readOrion (NYSE:OEC) reported Q2 updates on coatings and rubber segments. Specialty profitability was supported by pricing actions amid volatile oil-derived feedstock costs. Rubber adjusted EBITDA fell 61% YoY to $19 million. Orion said working capital added $4 million cash, capex fell to $25 million, and it retained full-year guidance assuming $80/bbl crude. Net debt was $961 million.
6 min readOEConnection (OEC) agreed to acquire UK fleet software platform Epyx and sister firms R2C Online and Business Gateway from Corpay Inc, backed by Francisco Partners. OEC plans to expand its European digital footprint in fleet servicing, maintenance and repair. Closing is expected this autumn, subject to regulatory approvals, with continuity for customers and partners.
4 min readOrion S.A. (OEC) reported Q2 results. GAAP earnings fell to $1.8 million, or $0.03 per share, from $9.0 million, or $0.16 per share, a year earlier. Revenue rose 7.4% to $500.9 million from $466.4 million, according to the company.
1 min readOrion S.A. (OEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ORION S.A. Exhibit 99.1 Orion S.A. Reports Second Quarter Earnings HOUSTON— August 5, 2026—Orion S.A. (NYSE: OEC), a specialty chemical company, today reported Second Quarter 2026 Net sales of $501 million, a 7% improvement from the prior year, as 9% higher average year-over-year
6 min readOrion S.A. (OEC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001609804 0001609804 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
3 min readOrion S.A. (NYSE: OEC) reported a Q1 2026 net loss of $9.9 million on net sales of $459.5 million, a 4% decrease year-over-year. Despite the Q1 loss, the company increased its full-year 2026 Adjusted EBITDA guidance to $170 million to $210 million, up from $160 million to $200 million,
2 min read
